Ref. No.: WOCK/SEC/SE/2025-26/063 27th January, 2026

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 **Scrip Code: 532300**	**National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 **NSE Symbol: WOCKPHARMA**

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release – "Wockhardt's Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance".

A copy of the same will also be uploaded on the Company's website www.wockhardt.com.

Kindly take the same on record please.

Thanking you,
For **Wockhardt Limited**
Rashmi Dinesh Mamtura
Digitally signed by Rashmi Dinesh Mamtura
Date: 2026.01.27 08:45:41 +05'30'

Rashmi Mamtura
Company Secretary`

Encls: A/a

PRESS RELEASE

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720
www.wockhardt.com

Mumbai, 27th January 2026

Wockhardt's Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance

Wockhardt announced that its novel intravenous antibiotic Foviscu® (WCK 4282) has successfully met the primary endpoint in a Phase 3 clinical trial in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis caused by Gram-negative bacteria, including extended-spectrum β-lactamase (ESBL)-producing pathogens. ESBL enzymes make many commonly used antibiotics ineffective and are a major cause of difficult-to-treat hospital infections.

With this milestone, Foviscu® becomes the fifth proprietary antibiotic from Wockhardt to complete a registration-enabling Phase 3 study, following Emrok®, Emrok O®, Miqnaf®, and Zaynich®, further strengthening Wockhardt's leadership in antibiotic discovery space.

In a randomized, double-blind Phase 3 study, Foviscu® was directly compared with meropenem, a "last-line" gold-standard carbapenem widely used for severe drug-resistant Gram-negative infections. At the Test-of-Cure visit, Foviscu® achieved a high clinical cure rate of 93.23% versus 92.31% with meropenem, thereby meeting the primary endpoint and demonstrating therapeutic equivalence with a similarly well-tolerated safety profile. This is the first Phase 3 head-to-head trial of an antibiotic specifically developed for ESBL infections compared with meropenem.

ICMR data show a high burden of ESBLs and rising resistance to commonly used antibiotics such as piperacillin/tazobactam and cefoperazone/sulbactam, increasingly forcing clinicians to rely on carbapenems (meropenem) and thereby accelerating carbapenem resistance. By providing an effective alternative, Foviscu® has the potential to reduce carbapenem use and strengthen antibiotic stewardship to curb antimicrobial resistance. Currently, approximately 65 lakh treatment courses of meropenem, piperacillin/tazobactam, and cefoperazone/sulbactam are used annually in India.

Foviscu® underwent a combined Phase 2 and Phase 3 program which enrolled 323 hospitalized cUTI and AP patients (Phase 2: 60; Phase 3: 263). The most common causative pathogens were Escherichia coli, Klebsiella spp., Enterobacter spp., and Pseudomonas spp. More than half of the Enterobacterales isolates (51.4%) were ESBL-positive, and 33.8% of Gram negatives were resistant to cefepime, underscoring the urgent need for stronger first-line treatment options in India, where ESBL prevalence is high.

About Foviscu® (WCK 4282)

Foviscu® is globally the only scientifically developed single-vial dosage form that combines pharmacodynamically optimized and clinically validated doses of tazobactam 2 g and cefepime 2 g, enabled by proprietary technology designed to ensure safety.

WCK 4282 has been extensively evaluated through a comprehensive global program covering clinical development, pharmacokinetics/pharmacodynamics (PK/PD), antimicrobial susceptibility testing methods, and microbiology. Phase 1 and renal impairment studies were conducted in The Netherlands, PK/PD studies in the US, Europe and India, and microbiology studies on global bacterial isolates in the US and India. Its

Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajinagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720
www.wockhardt.com

strong activity against ESBL-producing pathogens has been documented in several peer-reviewed publications in leading international journals. WCK 4282 has been accorded qualified infectious disease product (QIDP) designation by US FDA. The combined Phase 2/3 trial was partly supported by National Biopharma Mission (NBM), an initiative of Department of Biotechnology, Government of India.

About Wockhardt's Drug Discovery portfolio

Over the period of > 25 years, Wockhardt has focused its drug discovery efforts in the area of discovering novel medicines for multi-drug resistant infections. This has resulted in a portfolio of 6 products at various stages of clinical development and commercialization, each of which have been granted Qualified Infectious Disease Product status by the US FDA.